Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly Income from Continuing Operations came in at 43154000.0 in Q1 2026, up 7.04% year-on-year from 40316612.34 in Q1 2025, and down 11079.79% quarter-over-quarter from 386000.0 in Q4 2025.
Nektar Therapeutics (NKTR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 43154000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 7.04% year-over-year to 43154000.0 in Q1 2026; TTM through Mar 2026 was 117735000.0, a 13.44% decrease from a year earlier, with the FY2025 full-year figure at 121002000.0, down 28.5% from the prior year.
- Income from Continuing Operations declined to 43154000.0 in Q1 2026 per NKTR's latest filing, from 386000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 32054000.0 in Q4 2024 and bottomed at 159068000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 43154000.0 (2026), against an average of 48395058.82.
- Across the five-year window, Income from Continuing Operations tumbled 308.58% in 2023 and soared 176.18% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 20174000.0 in 2022, then tumbled by 308.58% to 42079000.0 in 2023, then jumped by 176.18% to 32054000.0 in 2024, then slumped by 101.2% to 386000.0 in 2025, then tumbled by 11079.79% to 43154000.0 in 2026.
- Per Business Quant, the three latest NKTR Income from Continuing Operations figures stand at 43154000.0 (Q1 2026), 386000.0 (Q4 2025), and 34988000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | -43.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.15 Mn |
| Dec 31, 2025 | -386,000.00 |
| Sep 30, 2025 | -34.99 Mn |
| Jun 30, 2025 | -39.21 Mn |
| Mar 31, 2025 | -46.42 Mn |
| Dec 31, 2024 | 32.05 Mn |
| Sep 30, 2024 | -37.06 Mn |
| Jun 30, 2024 | -52.36 Mn |
| Mar 31, 2024 | -36.80 Mn |
| Dec 31, 2023 | -42.08 Mn |
| Sep 30, 2023 | -45.84 Mn |
| Jun 30, 2023 | -51.12 Mn |
| Mar 31, 2023 | -137.02 Mn |
| Dec 31, 2022 | 20.17 Mn |
| Sep 30, 2022 | -59.05 Mn |
| Jun 30, 2022 | -159.07 Mn |
| Mar 31, 2022 | -90.39 Mn |
| Dec 31, 2021 | 378.80 Mn |
| Sep 30, 2021 | -129.71 Mn |
| Jun 30, 2021 | -125.52 Mn |